More than 85% of clinical trials are delayed due to slow enrollment and more than 30% of total trial time is spent recruiting patients.
There is a market need for a rapid and inexpensive screening test that can be used to easily identify APOE E4 carriers. These patients are at a higher genetic risk for developing Alzheimer's Disease (AD), and may also respond differently to various AD therapeutics. The Spartan APOE System is designed to meet this research need by providing a rapid, low cost, small footprint solution for patient screening at home or in clinic.
The test is performed using a non-invasive cheek swab, and provides full genotype results for the E2, E3 and E4 alleles in about one hour. This means that, for the first time, researchers can obtain results from cognitive and APOE pre-screening results all in the same visit. This greatly accelerates a variety of Alzheimer's research by facilitating subject recruitment.
The test is currently in use by North America and Europe's top memory clinics and clinical trial sites to increase enrollment in patient registries and as a pre-screening tool for clinical trials.
Clinical trials must embrace new knowledge and move forward with bold and innovative approaches aimed at eradicating Alzheimer's disease and not simply treating symptoms. . . The Spartan Cube is essentially the world's smallest and most portable device to test the APOE gene. And it does that on the spot, without having to send a biological sample to an external laboratory. Using just a cheek swab, the device can provide results within an hour and at a fraction of the cost.